Please ensure Javascript is enabled for purposes of website accessibility

Why Bausch Health Stock Popped on Friday

By George Budwell - Mar 14, 2020 at 2:00PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The stock rebounded on Friday in lockstep with the broader biopharmaceutical industry.

What happened

Bausch Health (BHC 2.03%), a multinational eye care and speciality pharmaceutical company, saw its shares gain a healthy 15.9% last Friday. Bausch, like many other healthcare companies, rebounded at the end of the week after President Trump's declaration of a national emergency, combined with the widespread assumption that Congress would ultimately pass a sweeping economic stimulus package with bipartisan support in the near future.

Even so, Bausch's shares still ended the week down by 10.3%. The good news is that the company's stock performed slightly better than the broader biopharmaceutical industry during this turbulent period. The closely watched iShares Nasdaq Biotechnology ETF, after all, shed over 12% of its value last week as a result of the growing concerns over the global economic and public health impact of the COVID-19 illness.

A road witht the word recovery painted across it.

Image source: Getty Images.

So what

Bausch's dramatic sell-off before Friday's rebound didn't make a whole lot of sense from a fundamental standpoint. While the company's debt-to-equity ratio is still worryingly high at 2,305, Bausch's management has taken a number of proactive steps to deleverage the biopharma's balance sheet and put it back on solid financial footing by the middle of the current decade.

What's more, the company's stock has consistently been one of the cheapest names in the space over the past few years. In fact, Bausch's shares were even trading at an absurdly low forward-looking price-to-sales ratio of 0.62 at the peak of last week's bloodbath. To put this valuation metric into the proper context, the average healthcare stock trades at no less than three times next year's projected sales. 

Now what

Can Bausch's stock continue to head higher in the weeks ahead? With the COVID-19 illness spooking investors, there's no way to know what's in store for Bausch for the remainder of the year. That said, this company is grossly undervalued relative to its long-term growth prospects. So if you're willing to ride out this short-term volatility, it might be a good idea to grab a few shares of this diversified healthcare stock on any further weakness. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Bausch Health Companies Inc. Stock Quote
Bausch Health Companies Inc.
BHC
$8.53 (2.03%) $0.17
iShares Trust - iShares Nasdaq Biotechnology ETF Stock Quote
iShares Trust - iShares Nasdaq Biotechnology ETF
IBB
$120.17 (2.16%) $2.54

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.